STAPLE TYPE OLIGONUCLEOTIDE AND DRUG COMPRISING THE SAME

摘要

It is intended to provide an oligonucleotide and a drug to thereby solve problems occurring in existing oigonucleotides, for example, being unstable because of being opened at both ends, and showing toxicity caused by phosphorothioate when modified with phosphorothioate (S-modification) to elevate the stability to digesting enzymes. More specifically speaking, a staple type oligonucleotide and a drug containing the same as the active ingredient. More particularly, a transcriptional factor inhibitor, an antisense oligonucleotide or an siRNA, in greater detail, a drug for preventing, treating or improving inflammation, autoimmune diseases, central diseases, reperfusion injury in ischemic diseases, worsened prognosis after organ transplantation or organ operation or restenosis after PTCA. Still specifically speaking, a drug for preventing, treating or improving arthritis, dermatitis, nephritis, hepatitis, renal failure, cystitis, prostatitis, urethritis, ulcerative colitis, Crohn's disease, rheumatoid arthritis or arthritis deformans, atopic dermatitis, contact dermatitis, prosiasis, skin ulcer or bed sore.